InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer

被引：5
|
作者：
Blank, S. [1 ]
Mahdi, H. [2 ]
Tehrani, O. [3 ]
Ghamande, S. [4 ]
Jain, S. [5 ]
Nicacio, L. [6 ]
Soumaoro, I. [7 ]
O'Malley, D. M. [8 ]
机构：
[1] Icahn Sch Med Mt Sinai, Mt Sinai Hlth Syst, Div Gynecol Oncol, Obstet Gynecol & Reprod Sci, New York, NY 10029 USA
[2] Cleveland Clin, ObGyn & Womens Hlth Inst, Gynecol Oncol Sect, Cleveland, OH 44106 USA
[3] Stanford Univ, Div Oncol, Med, Palo Alto, CA 94304 USA
[4] Augusta Univ, Georgia Canc Ctr, OB GYN, Augusta, GA USA
[5] Seattle Genet Inc, Clin Res, Bothell, WA USA
[6] Seattle Genet Inc, Dev, Bothell, WA USA
[7] Genmab, Clin Res, Princeton, NJ USA
[8] Ohio State Univ, James Comprehens Canc Ctr, Gynecol Oncol, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
882TiP
引用
收藏
页码：S646 / S646
页数：1
相关论文
共 50 条
  • [1] Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
    Mahdi, Haider
    Schuster, Steven Robert
    O'Malley, David M.
    McNamara, Donna M.
    Rangwala, Reshma A.
    Liang, Shang-Ying
    Jain, Shweta
    Nicacio, Leonardo
    Chon, Hye Sook
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors
    Hong, D.
    Fayette, J.
    Birnbaum, A.
    Steuer, C.
    Taylor, M. H.
    George, T. J.
    Lacy, J.
    Beca, F.
    Nicacio, L. V.
    Soumaoro, I.
    Cho, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S816 - S816
  • [3] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [4] Weekly gemcitabine in patients with relapsed platinum-resistant ovarian or peritoneal cancer. Results of phase II study
    Czerniawska, Malgorzata
    Jagiello-Gruszfeld, Agnieszka
    Zbrzezniak, Jolanta
    Wachula, Ewa
    Szablowska-Siwik, Sylwia
    Sikorska, Magdalena
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [5] innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.
    Le, Xiuning
    Carneiro, Benedito A.
    Hong, David S.
    Birnbaum, Ariel E.
    Taylor, Matthew H.
    Patel, Shetal Arvind
    William, William Nassib
    Wang, Bokai
    Beca, Francisco
    Jain, Shweta
    Soumaoro, Ibrahima
    Dunn, Lara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Keldsen, N
    Havsteen, H
    Vergote, I
    Bertelsen, K
    Jakobsen, A
    GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 118 - 122
  • [7] Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S145 - S145
  • [8] A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum-resistant ovarian cancer
    Odunsi, K.
    Ghamande, S.
    Macfee, M.
    Yu, A. Yin Chieh
    Lele, S. B.
    Rodabaugh, K. J.
    Thomas, B.
    Zamboni, W. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer
    Hirte, H. W.
    McGuire, W. P., III
    Edwards, R. P.
    Husain, A.
    Hoskins, P.
    Michels, J. E.
    Matulonis, U.
    Sexton, C.
    Fox, J. A.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Cannistra, Stephen A.
    Matulonis, Ursula A.
    Penson, Richard T.
    Hambleton, Julie
    Dupont, Jakob
    Mackey, Howard
    Douglas, Jeffrey
    Burger, Robert A.
    Armstrong, Deborah
    Wenham, Robert
    McGuire, William
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
12345